Skip to content

Ultragenyx Pharmaceutical

US · RARE #3012 by market cap Listed 1970
16.48 -0.74 -4.30%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:31

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 24 in the most recent period (2026/Q3).
  • Total institutional ownership rose 7.0 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
117.65% +7.01pp
Institutions
364 -24
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund67.43%
Hedge Fund36.94%
Public Company5.44%
VC/PE Fund4.01%
Individual/Insider3.49%
Private Company2.40%
Insurance Company0.51%
Government Pension Fund0.36%
Endowment Fund0.25%
Family Office/Trust0.25%

Top holders as of 2026-09-30

BlackRock 11.25% · 11.43M sh
Vanguard Portfolio Management, LLC 8.28% · 8.42M sh
RTW Investments, LP 7.67% · 7.80M sh
State Street Global Advisors 7.42% · 7.54M sh
AQR Capital Management 6.43% · 6.53M sh
Madison Avenue Partners, LP 6.21% · 6.31M sh
Vanguard Capital Management, LLC 4.23% · 4.30M sh
Two Sigma Investments, LP 3.56% · 3.62M sh
Sands Capital Management, LLC 3.11% · 3.16M sh
Frontier Capital Management 2.90% · 2.85M sh
Jacobs Levy Equity Management Inc 2.89% · 2.94M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 30 buys · 20 sells

NameRoleStake
Emil Kakkis Chief Executive Officer 2.71%
Thomas Kassberg Former Chief Business Officer & Executive VP 0.23%
Dennis Huang Chief Technical Operations Officer and Executive VP of Gene Therapy Operations 0.10%
John Pinion Chief Quality Operations Officer & Executive VP of Translational Sciences 0.08%
Erik Harris Executive Vice President 0.06%
Eric Crombez Chief Medical Officer & Executive VP 0.05%
Karah Parschauer Chief Legal Officer & Executive VP of Corporate Affairs 0.04%
Michael Narachi Independent Director 0.03%
Daniel Welch Independent Non-Executive Chairperson 0.03%
Theodore Huizenga Senior VP, Corporate Controller & Principal Accounting Officer 0.03%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-14 Howard Horn Executive VP of Corporate Strategy & CFO Open Market Disposition -7,066 $15.27
2026-09-14 Theodore Huizenga Senior VP, Corporate Controller & Principal Accounting Officer Open Market Disposition -1,283 $13.57
2026-09-02 Theodore Huizenga Senior VP, Corporate Controller & Principal Accounting Officer Open Market Disposition -161 $13.99
2026-08-02 Howard Horn Executive VP of Corporate Strategy & CFO Open Market Disposition -4,696 $24.92
2026-08-02 Karah Parschauer Chief Legal Officer & Executive VP of Corporate Affairs Open Market Disposition -1,900 $24.92
2026-06-30 Howard Horn Executive VP of Corporate Strategy & CFO Open Market Disposition -4,698 $33.13
2026-06-14 Corazon Sanders Independent Director Open Market Disposition -2,000 $25.05
2026-06-14 Karah Parschauer Chief Legal Officer & Executive VP of Corporate Affairs Open Market Disposition -1,899 $24.62
2026-05-31 Howard Horn Executive VP of Corporate Strategy & CFO Open Market Disposition -4,653 $23.77
2026-05-17 Shehnaaz Suliman Independent Director Open Market Disposition -5,740 $25.12
2026-05-13 Daniel Welch Independent Non-Executive Chairperson Other Acquisition +7,751 --
2026-05-13 Daniel Welch Independent Non-Executive Chairperson Other Derivative Acquisition +14,058 $25.80
2026-05-13 Matthew Fust Independent Director Other Acquisition +7,751 --
2026-05-13 Matthew Fust Independent Director Other Derivative Acquisition +14,058 $25.80
2026-05-13 Shehnaaz Suliman Independent Director Other Acquisition +7,751 --
2026-05-13 Shehnaaz Suliman Independent Director Other Derivative Acquisition +14,058 $25.80
2026-05-13 Deborah Dunsire Independent Director Other Acquisition +7,751 --
2026-05-13 Deborah Dunsire Independent Director Other Derivative Acquisition +14,058 $25.80
2026-05-13 Corazon Sanders Independent Director Other Acquisition +7,751 --
2026-05-13 Corazon Sanders Independent Director Other Derivative Acquisition +14,058 $25.80

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:31:44 · For reference only, not investment advice and not tailored to your situation.

Ultragenyx Pharmaceutical discussion 0 comments

Add a comment